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MigrationWe aimed to ascertain the role of microRNAs (miRNAs) in regulating human endometrial cancer
stem cells (HuECSCs). The expression level of miRNA-134 (miR-134), a member of the DLK1-DIO3
genomic imprinted miRNA cluster, differed signiﬁcantly between HuECSCs and human endometrial
cancer cells (HuECCs). miR-134 inhibited HuECSCs proliferation and migration by targeting protein
O-glucosyltransferase 1 (POGLUT1) expression. Exogenous miR-134 overexpression downregulated
POGLUT1 and Notch pathway proteins in HuECSCs in vitro. miR-134 overexpression affected the
G2/M phase of HuECSCs and suppressed the growth of xenograft tumours formed. Thus, endogenous
miR-134 regulation in HuECSCs may suppress tumourigenesis in human endometrial carcinoma.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Type II endometrial carcinoma (EC) is a common gynaecologic
malignancy having a poor prognosis; it is oestrogen receptor-neg-
ative, poorly differentiated, and of high grade [1–3]. CD44+/
CD133+ carcinoma stem cells from human type II EC cell lines
KLE and AN3CA play a crucial role in proliferation, metastasis,
recurrence, and development of chemotherapy resistance [4].
However, the potential molecular mechanisms involved prolifera-
tion and migration of CD44+/CD133+ carcinoma stem cells are
poorly understood. MicroRNAs (miRNAs) are 19–23-nucleotide
(nt) non-coding RNAs regulating biological processes essential for
cancer initiation and progression, leading to affect the stability of
their target genes by the binding of speciﬁc target mRNAs [5–7].
miRNAs can function as oncogenes or tumour suppressors
[8–11]. In previous studies, Dong et al. reported that some microR-
NA inﬂuenced epithelial–mesenchymal transition, cancer stem cell‘‘stemness’’ of human endometrial cancer by targeting the PTEN-
PI3K-AKT-mTOR axis, EGFR/HER2 or VEGF-related pathway
[12,13]. On the other hand, many miRNAs are part of a unique
group termed the DLK1-DIO3 genomic imprinted miRNA cluster
[14–18]. In humans, this region contains paternally expressed
genes delta-like 1 homolog (DLK1), retrotransposon-like 1 (RTL1),
and iodothyronine deiodinase 3 (DIO3), as well as maternally
expressed genes MEG3, MEG8, and antisense RTL1 [14]. The
DLK1-DIO3 region has undergone important evolutionary changes,
the most important being the acquisition of the imprinting control
region. It hosts 53 miRNAs on the forward strand and 1 miRNA on
the reverse strand [14]. In the DLK1-DIO3 region, the 50-end of the
domain harbours DLK1, while DIO3 lies at the 30-end [15]. Lethality
and developmental abnormalities observed in conceptuses with
maternal and paternal uniparental chromosome 14q32 disomy
demonstrate the need for the correct dosage of imprinted genes
in this domain [15]. Some miRNAs in the DLK1-DIO3 miRNA
cluster regulate carcinoma proliferation and invasion [16–18].
Coordinated upregulation of the DLK1-DIO3 miRNA cluster at
human chromosome 14q32.2 might deﬁne a novel molecular
(stem cell-like) subtype of hepatocellular carcinoma associated
with poor survival [16]. Inhibiting endogenous miRNA-134
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reverses the suppressive effects of hepatocyte nuclear factor 4a
on Kirsten rat sarcoma viral oncogene homolog (KRAS) expression
and hepatocellular carcinoma malignancy [17]. Several miRNAs in
the DLK1-DIO3 miRNA cluster repress epithelial–mesenchymal
transition in breast cancer by targeting the twist family bHLH
transcription factor 1 (TWIST1) gene signalling network [18].
Protein O-glucosyltransferase 1 (POGLUT1) was initially identi-
ﬁed in CD34+ cells of patients with acute myeloid leukaemia trans-
formed from myelodysplastic syndrome [19–21]. The C-terminus
of POGLUT1 contains a highly conserved domain (CAP10) and an
endoplasmic reticulum (ER) retention signal motif (KTEL); the
N-terminus contains a hydrophobic signal peptide [21]. POGLUT1
is overexpressed in several leukaemia cell lines [19–21] and is an
essential regulator of Notch signalling [19,21].
Many studies have been demonstrated that Notch pathway
regulates cell fate of proliferation and growth in mammal
[19,20,22–26]. Core components of Notch signalling are trans-
membrane ligands (Delta and Serrate/Jagged) and receptors (Notch
1–4) and transcription factor CSL (C-promotor-binding factor)
[19,20,22–26]. There are four types Notch receptors are single pass
transmembrane glycoproteins, Notch extracellular domains
(NECDs) 8 contain 29–36 tandemly organized N-terminal epider-
mal growth factor (EGF)-like repeats in mammalian. Upon translo-
cation to the nucleus, Notch intracellular domain binds to CSL
(CBF1/Su(H)/Lag-1), a transcriptional repressor that recruits the
co-activator Mastermind, and the complex activates the expression
of Notch target genes [19,20,22–26]. Previous reports revealed that
Notch pathway could be regulated by glycosylation [7,11,12,18].
Because the O-fucosylation and O-glucosylation were two different
special modiﬁcation ways of NECDs [19,20,22–26]. The O-fucosyla-
tion induced ligand binding to Notch-1 receptors, while the
O-glucosylation induced ligand cleaving Notch1 receptors
[19,20,22–26]. To date, POGLUT1 has been demonstrated as an
O-glucosyltransferase to be able to hydrolyze UDP-Glc in vitro
[19,20,22–26]. Moreover, O-glucosyltransferase could regulate
folding and/or trafﬁcking of Notch receptor and allow signalling
at the cell membrane [19,20,22–26].
In here, we discovered in this study that miR-134 directly sup-
presses POGLUT1 and that miR-134 overexpression inhibits human
EC stem cell (HuECSCs) proliferation and migration both in vitro
and in vivo. Our results indicate that increased expression of exog-
enous mature miR-134 may inhibit HuECSCs growth by reducing
POGLUT1 expression. Thus, POGLUT1 might be an important new
therapeutic target for human EC.2. Materials and methods
2.1. Isolation and in vitro expansion of CD44+/CD133+ tumour cells by
ﬂuorescence-activated cell sorting
EC tissues were collected from the International Peace Mater-
nity and Child Health Hospital (Shanghai, China) between May
2012 and December 2012 (Supplement Table 1). CD44+/CD133+
cell subpopulations were isolated from tumour samples as previ-
ously described [4]. After isolation, single cells were plated at
1000 cells/mL in DMEM: F12 (HyClone) supplemented with
10 ng/mL basic ﬁbroblast growth factor, 10 ng/mL epidermal
growth factor, 5 lg/mL insulin, and 0.5% bovine serum albumin
(all from Sigma–Aldrich). CD44+/CD133+ cells were cultured under
the above conditions as non-adherent spherical clusters
(HuECSCs). CD44/CD133 cells were cultured under general con-
ditions as adherent clusters (HuECCs). All cells were cultured under
the same conditions until passage 4 before further experiments.2.2. miR-134 overexpression vector construction
A miRNA expression plasmid was constructed as previously
described [9]. Brieﬂy, in the negative control plasmid, 9 nucleotides
in the miR-134 seed sequence were mutated (GGTCAGTGT to GcT-
gAGacT). HuECSCs were seeded at 3  107 per well in diameter
10 cm cell petri dish and transfected with 30 lg wild-type (WT)
or mutant (Mut) miR-134 vector using Lipofectamine 2000
(Invitrogen).
2.3. Luciferase report assay
NIH-3T3 mouse embryonic ﬁbroblast cells and HuECSCs were
seeded at 3  104 per well in 48-well plates and co-transfected
with 400 ng pRNAT-CMV32-mir134, pRNAT-CMV32-mir134-Mut,
or pRNAT-CMV32 (empty vector); 20 ng pGL3 cm-Poglut1-3UTR
or pGL3 cm-Poglut1-3UTR-Mut; and pRl-TK (Promega, Madison,
USA) using Lipofectamine 2000. Luciferase activity was measured
after 48 h using the Dual-Luciferase Reporter Assay System (Pro-
mega, Madison, USA) [9].
2.4. RNA extraction and quantitative real-time PCR analysis
Total RNA was isolated from each cell type using TRIzol Reagent
(Invitrogen). RNA samples were treated with DNase I (Sigma–
Aldrich), quantiﬁed, and reverse-transcribed into cDNA using the
ReverTra Ace-a First Strand cDNA Synthesis Kit (Toyobo). Quanti-
tative real-time PCR (qRT-PCR) was conducted using a RealPlex4
real-time PCR detection system (Eppendorf, Germany) with SyBR
Green Realtime PCR Master Mix (Toyobo) at 40 cycles of denatur-
ation at 95 C for 15 s and annealing at 58 C for 45 s. Target cDNA
was measured by relative quantiﬁcation. A comparative threshold
cycle (Ct) was used to determine relative gene expression normal-
ized to 18S rRNA. For each sample, Ct values were normalized
using the formula DCt = Ct_genes  Ct_18S RNA. Relative
expression levels were calculated using the formula DDCt = DCt_
all_groups  DCt_blankcontrol_group. Values applied to plot rela-
tive gene expression were calculated using the expression 2DDCt.
Primers used for cDNA ampliﬁcation were as previously described
[20].
2.5. Cell proliferation assay
Cells were seeded at 2  103 per well in 96-well plates and cul-
tured in DMEM supplemented with 10% foetal bovine serum (FBS)
at 37 C under 5% CO2 until 85% conﬂuence. Methyl thiazolyl tetra-
zolium (MTT; Sigma Chemicals) (5 mg/mL) was added at different
time points and incubated for a further 4 h. The reaction was
terminated by adding 150 lL/well dimethyl sulphoxide (Sigma
Chemicals). Cells were lysed for 15 min, and plates were gently
shaken for 5 min. Absorbance at 490 nm was determined using a
Model 680 Microplate Reader (Bio-Rad).
2.6. miRNA microarray analysis
RNA labelling and hybridization on miRNA microarray chips
were conducted as previously described [27,28]. Total RNA
(50 lg) was puriﬁed using the mirVANA miRNA isolation kit
(Ambion, Austin, TX) to enrich the small RNA fraction. Puriﬁed
RNA was labelled with ﬂuorescein, and hybridization was carried
out on the Agilent Mammalian miRNA Array (Shanghai genomePi-
lot Technology, Inc., Shanghai, China) containing oligonucleotide
probes for 2844 mature miRNA genes in triplicate (1823 human,
648 mouse, and 373 rat sequences). RNA samples were analysed
on an individual chip. Hybridization signals were detected, and
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values were normalized to per-chip mean values.
2.7. Northern blotting
For all cell treatment groups, 20 lg high-quality total RNA was
analysed on a denaturing gel (7.5 M urea, 12% PAA) and transferred
to a Hybond N+ nylon membrane (Amersham, Freiburg, Germany).
Membranes were cross-linked using ultraviolet light for 30 s at
1200 mJ/cm2 and hybridized to the miR-134 antisense Starﬁre
probe, 5’-TTGGTGACTAGGTGGCCCACAGG-3’ (IDT, Coralville, IA)
to detect 22-nt miR-134 fragments. Membranes were washed
and exposed to Kodak XAR-5 ﬁlm for 20–40 h (Sigma–Aldrich). A
human U6 snRNA probe (50-GCAGGGGCCATGCTAATCTTCTCTG-
TATCG-30) was used as a positive control (exposure time,
15–30 min) [10].
2.8. Western blotting
Total protein extracts of each cell treatment group were
resolved by 12% SDS–PAGE and transferred onto polyvinylidene
diﬂuoride (Millipore) membranes. Membranes were blocked and
then washed 4 times for 15 min with Tris-buffered saline contain-
ing 0.3% Tween-20 at room temperature and then incubated with
primary polyclonal antibodies (Supplement Table 3) [10]. Mem-
branes were washed and incubated at room temperature with sec-
ondary peroxidase-linked goat anti-rabbit IgG (1:1000 dilution;
Santa Cruz Biotechnology) for 1 h. Protein bands were visualized
by enhanced chemiluminescence (ECL kit; Pierce Biotechnology)
and autoradiography.
2.9. Flow cytometric analysis of cell cycle by propidium iodide staining
Cells of each group were seeded at 3  105 per well in 6-well
plates and cultured until 85% conﬂuence. The cells were then
washed with PBS thrice and collected by centrifugation (Allegra
X-22R, Beckman Coulter) at 1000g for 5 min. Cell pellets were
resuspended in 1 mL PBS, ﬁxed in 70% ice-cold ethanol, and kept
in a freezer for more than 48 h. Before ﬂow cytometry, the ﬁxed
cells were centrifuged, washed twice with PBS, and resuspended
in propidium iodide (PI) staining solution (50 lL/mL PI and
250 lg/mL RNase A; Sigma–Aldrich). The cell suspension was incu-
bated for 30 min at 4 C and analysed by FACS (Quanta SC FlowCy-
tometry, Beckman Coulter Commercial Enterprise (China) Co. Ltd.,
Shanghai, China). Using CellQuest software, 20000 events were
acquired for analysis.
2.10. Soft agar colony-formation assay
Soft agar assays were set up in 6-well plates. The base layer of
each well had 2 mL of 1 medium (DMEM + 10% FBS) and 0.6%
low-melting agarose. Plates were chilled at 4 C until solid. A
1-mL growth agar layer comprising 1  104 cells suspended in
1 medium and 0.3% low-melting agarose was poured over this.
Plates were again chilled at 4 C until the growth layer congealed.
Additional 1 mL 1 medium without agarose was added over the
growth layer on day 0 and again on day 15 of growth. Cells were
allowed to grow at 37 C for 1 month and total colonies counted.
Assays were repeated thrice. Results were analysed by paired t-test
using PRISM Graphpad [9].
2.11. Transwell migration assay
Cells (2  105) were resuspended in 200 lL serum-free medium
and seeded on the top chamber of 8.0-lm pore, 6.5-mm polycar-
bonate Transwell ﬁlters (Corning). Medium (600 lL) containing10% FBS was added to the bottom chamber. Cells were allowed to
migrate for 24 h at 37 C in a humidiﬁed incubator with 5% CO2.
Cells attached to the lower surface of the membrane were ﬁxed in
4% paraformaldehyde at room temperature for 30 min and stained
with crystal violet (Beyotime Institute of Biotechnology, China).
Cells on the lower surface of the ﬁlters were counted using a micro-
scope. Five ﬁelds were counted for each Transwell ﬁlter [9].2.12. In vivo xenograft experiments
Logarithmically growing HuECSCs (1  105) were inoculated
into BALB/c nude mice. Each experimental group comprised 4
mice. After 12 weeks, the mice were sacriﬁced and tumours
surgically excised [4]. Tumours were weighed, and the volume
was calculated as follows: tumour volume (mm3) = (ab2)/2, where
a represents the longest axis (mm) and b the shortest axis (mm).
2.13. Statistical analysis
Each experiment was performed as least 3 times; data are pre-
sented as mean ± SE where applicable. Differences were evaluated
using Student’s t-tests. P values < 0.05 were considered statistically
signiﬁcant.
3. Results
3.1. Mature miR-134 in the DLK1-DIO3 miRNA cluster was
downregulated in CD44+/CD133+ HuECSCs
The HuECSCs CD44+/CD133+ subpopulation in both KLE and
AN3CA is relatively small [4]. Therefore, we used magnetic
activated cell sorting to isolate and enrich the CD44+ and
CD133+ subpopulations from the tissues of 4 EC patients [4]. Then,
we used miRNA microarray analyses to identify differentially
expressed mRNAs in CD44+/CD133+ HuECSCs and CD44/
CD133HuECSCs. The expression of 1 miRNA decreased by >0.2-
fold in HuECSCs compared to that in HuECCs, and the expression
of 9 miRNAs increased by >2-fold (Supplement Table 2). miR-134
was expressed at signiﬁcantly lower levels in HuECSCs than in
HuECCs (Fig. 1A). To conﬁrm this ﬁnding, northern blotting and
miRNA-speciﬁc quantitative reverse transcription-PCR was used
to measure mature miR-134 expression in HuECSCs and HuECCs.
miR-134 hybridization signals were weaker in HuECSCs extracts
than in HuECC extracts, revealing that miR-134 was downregu-
lated in HuECSCs (Fig. 1B). miR-134 expression levels were found
to be signiﬁcantly lower in HuECSCs than in HuECCs (Fig. 1C).
3.2. Identiﬁcation of miR-134 binding sites in the POGLUT1 30-
untranslated region
ThemiRBase Target databasewas used to analyse precursormiR-
NA sequences, mature miRNA sequences, chromosomal locations,
miR-134 length, and potential target sites in POGLUT1. A putative
7-nt miRNA target site was identiﬁed in the human POGLUT1mRNA
30-untranslated region (30-UTR) (Fig. 1D). To examine whether
mature miR-134 regulated POGLUT1 expression, a luciferase repor-
ter containing WT or Mut POGLUT1 30-UTR miR-134 binding site, or
an empty plasmid control was co-transfectedwithmiR-134 expres-
sion vectors (WT-miR-134, Mut-miR-134, or empty vector control)
into NIH-3T3 cells and HuECSCs. WT POGLUT1 30-UTR luciferase
reporter activity was signiﬁcantly inhibited following miR-134 co-
transfection; Mut POGLUT1 30-UTR luciferase reporter activity was
unaffected by the miR-134 co-transfection not only in NIH-3T3
cells, but also in HuECSCs (Fig. 1E). Thus, miR-134 targets POGLUT1
mRNA by speciﬁcally binding to its 30-UTR.
Fig. 1. miRNA expression in HuECSCs and HuECC DLK1-DIO3 miRNA clusters and identiﬁcation of miR-134 binding sites in the POGLUT1 30-UTR. (A) Representative
microarray hybridization signals and clustering trees for HuECSCs vs. HuECCs. (B) Northern blot analysis of miR-134 expression showing strong hybridization signals for
miR-134 from HuECCs compared to HuECSCs. The human U6 probe was used as the loading control. (C) qRT-PCR analysis showing markedly higher miR-134 expression in
HuECCs than in HuECSCs. The results are normalized to 18S rRNA. ⁄⁄P < 0.01 vs. HuECSCs, #P > 0.05 vs. HuECSCs; n = 5. (D) Identiﬁcation of miR-134 binding sites in
the POGLUT1 30-UTR. (E) Luciferase reporter gene assays showing that miR-134 inhibited WT POGLUT1 30-UTR luciferase activity. ⁄P < 0.05 and #P > 0.05 vs. pRNT-CMV32;
n = 3. 2-DDCt, comparative threshold cycle; ORF, open reading frame.
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MTT assays revealed signiﬁcant differences in the viability of
HuECSCs transfected with WT or Mut miR-134. Compared to Mut
miR-134-transfected cells, WT miR-134 overexpression signiﬁ-
cantly reduced HuECSCs proliferation after 24 and 48 h (Fig. 2A),
indicating that exogenous miR-134 overexpression inhibits
HuECSCs growth in vitro. Furthermore, ﬂow cytometry revealed
signiﬁcant cell cycle arrest in the WT miR-134-transfected
HuECSCs. Compared to the Mut miR-134-transfected HuECSCs,
G2/M was arrested in WT miR-134-transfected HuECSCs, and the
percentage of HuECSCs in the S phase signiﬁcantly decreased at
48 h (Fig. 2D). Thus, exogenous miR-134 overexpression sup-
presses proliferation.
3.4. miR-134 weakened ability of HuECSCs to form sphere clone and
multi-drug resistance
In order to evaluate whether the miR-134 weakened ability of
HuECSCs to form sphere clone, the clone forming rates were
counted in each group. We found that the clone forming rate ofmiR-134-transfected cells (11.18% ± 3.59%) was signiﬁcantly less
than it in Mut miR-134-transfected cells (58.59% ± 6.25%, Supple-
ment Fig. S1A). Besides, in order to evaluate the multi-drug resis-
tance of miR-134-transfected HuECSCs and Mut miR-134-
transfected HuECSCs, the inhibitory rates of cisplatin and paclitaxel
(0, 30, 60, and 90 nmol/ml) were measured using the MTT prolifer-
ation assay. The growth of both miR-134- and Mut miR-134-trans-
fected HuECSCs were inhibited by cisplatin and paclitaxel;
however, Mut miR-134-transfected HuECSCs were signiﬁcantly
less susceptible to the cytotoxic effects of both drugs (Supplement
Fig. S1B). Thus, Mut miR-134-transfected HuECSCs were more
resistant to cisplatin and paclitaxel than miR-134-transfected
HuECSCs. So, above results suggested that the miR-134 weakened
ability of HuECSCs to form sphere clone and multi-drug resistance.
3.5. miR-134 suppressed HuECSCs migration
We examined whether exogenous miR-134 overexpression
could suppress HuECSCs migration. In the soft agar colony-forma-
tion assay, miR-134-transfected cells plated at low density formed
substantially fewer colonies (colony-formation efﬁciency: 16.86% ±
Fig. 2. miR-134 regulates HuECSCs proliferation, cell cycle, and migration. (A) MTT assay showing markedly higher inhibition rates of WT miR-134-transfected (miR-134)
HuECSCs compared to Mut miR-134 (miR-mut)-transfected HuECSCs from 0 to 48 h post-transfection. ⁄⁄P < 0.01 vs. miR-mut-transfected group, ⁄P < 0.05 vs.
miR-mut-transfected group, #P > 0.05 vs. miR-mut-transfected group; n = 5. (B) Soft agar colony-formation assay showing substantially more colonies formed by
miR-mut-transfected HuECSCs than miR-134-transfected HuECSCs. ⁄P < 0.05 vs. miR-mut-transfected group; n = 5. (C) Transwell migration assay showing signiﬁcantly fewer
migrating miR-134-transfected HuECSCs per well than miR-mut-transfected HuECSCs. ⁄⁄P < 0.01 vs. miR-mut-transfected group; n = 5. (D) Flow cytometry assay showing G2/
M arrest and markedly decreased percentage of S phase cells among miR-134-transfected HuECSCs.
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efﬁciency: 37.65% ± 5.76%; Fig. 2B).
In the Transwell migration assays, there were signiﬁcantly
fewer migrating WT miR-134-transfected cells/well (migrating cell
numbers: 40 ± 7) than Mut miR-134-transfected cells/well
(migrating cell numbers: 129 ± 18, Fig. 2C). These data indicate
that exogenous miR-134 overexpression downregulates HuECSCs
migration.
3.6. miR-134 overexpression in HuECSCs attenuated POGLUT1 and
Notch pathway protein expression
We used qRT-PCR and Western blotting to evaluate the expres-
sion levels of POGLUT1 and Notch pathway proteins Notch-1, C
promoter-binding factor 1 (CBF1), hes family bHLH transcription
factor 1 (HES1), and p27 in WT and Mut miR-134-transfected
HuECSCs. At 48 h, Poglut1, Cbf1, and Hes1 mRNA levels were all
signiﬁcantly lower in WT miR-134-transfected cells than in Mut-
miR-134-transfected cells (Fig. 3A). Western blotting conﬁrmed
that the expression of POGLUT1 and Notch pathway proteins was
signiﬁcantly lower in WT miR-134-transfected HuECSCs compared
to Mut miR-134-transfected HuECSCs (Fig. 3B). However, both
qRT-PCR and Western blotting showed that p27 expression was
higher in WT miR-134-transfected HuECSCs than in Mut miR-
134-transfected HuECSCs (Fig. 3A and B). Therefore, exogenous
miR-134 overexpression downregulates both endogenous
POGLUT1 and Notch pathway proteins in HuECSCs.
3.7. miR-134 overexpression inhibited HuECSCs xenograft growth
The effect of miR-134 overexpression on tumour growth in vivo
was investigated by subcutaneous inoculation of WT or Mut miR-
134-transfected HuECSCs into nude mice. WTmiR-134 overexpres-
sion signiﬁcantly reduced tumour volume (Fig. 4A); all mice inoc-
ulated with Mut miR-134-transfected HuECSCs developed tumours
approximately 6 weeks after injection, whereas at the same time
point, none of the mice inoculated with WT miR-134-transfectedHuECSCs developed tumours. Although both experimental groups
eventually developed tumours, the tumours formed by WT
miR-134-transfected cells grew more slowly than tumours formed
by Mut miR-134-transfected cells (Fig. 4B). Furthermore, when the
mice were sacriﬁced 12 weeks after injection, the tumours from
the Mut miR-134-transfected group were signiﬁcantly heavier
than those of the WT miR-134-transfected group (Fig. 4C).
Representative hematoxylin and eosin (HE)-stained sections of all
subcutaneous xenograft tumours from both WT and Mut
miR-134-transfected HuECSCs were categorized as moderately to
poorly differentiated serous EC (grade II) (Fig. 4D). We also mea-
sured the expression of the cell proliferation marker Ki-67 in
tumour sections using immunohistochemistry. Tumours from
Mut miR-134-transfected cells had positive or strongly positive
Ki-67 staining, whereas tumours from WT miR-134-transfected
cells exhibited weak Ki-67 immunoreactivity (Fig. 4E). Thus, xeno-
grafts formed by WT miR-134-overexpressing cells were smaller
and with reduced proliferation than those formed by Mut
miR-134-overexpressing cells.
4. Discussion
Our team ﬁrst reported the existence of a CD44+/CD133+ sub-
population in type II EC [4]. CD44+/CD133+ HuECSCs are highly
proliferative, highly migratory, multidrug resistant, and highly
tumourigenic [4]. We hypothesized that HuECSCs are the plausible
root cause of metastasis or recurrence in EC; however, the mecha-
nisms are still not understood. Using our previous miRNA research
ﬁndings as a foundation, we focused on miRNA regulation to dis-
cover the regulatory factors and target genes underlying HuECSCs
proliferation and migration to elucidate its mechanism. Here, we
used miRNA microarray to analyse HuECC and HuECSCs miRNA
expression patterns. Interestingly, we found a unique miRNA group
among the differentially expressed miRNAs: the DLK1-DIO3 miR-
NA cluster. Some HuECSCs and HuECC miRNAs had signiﬁcantly
different expression, and these were among the DLK1-DIO3 miRNA
cluster. This cluster at 14q32.2 is closely related to tumour
Fig. 3. MiR-134 regulates the expression of POGLUT1 and Notch pathway proteins in HuECSCs. (A) The qRT-PCR analysis of mRNA expression of POGLUT1 and Notch pathway
proteins. The results were normalized to 18S rRNA. ⁄⁄P < 0.01 vs. miR-mut-transfected group, #P > 0.05 vs. miR-mut-transfected group; n = 5. (B) Western blotting analysis of
expression of POGLUT1 and Notch pathway proteins. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the loading control. ⁄⁄P < 0.01 vs. miR-mut-
transfected group, ⁄P < 0.05 vs. miR-mut-transfected group, #P > 0.05 vs. miR-mut-transfected group; n = 5.
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that HuECSCs miR-134 expression in the DLK1-DIO3miRNA cluster
was signiﬁcantly decreased. Zha et al. used genome-wide screening
and determined that miR-134 inhibited focal adhesion kinase
phosphorylation and RhoA activation downstream of the b1 inte-
grin pathway, thereby decreasing stress ﬁbre formation and cell
adhesion in hepatocellular carcinoma [29]. Li et al. reported that
miR-134 inhibited transforming growth factor-b1-induced
epithelial–mesenchymal transition by targeting forkhead box M1
in non-small cell lung cancer cells [30]. Yin et al. indicated that
inhibiting endogenous miR-134 partially reversed the suppressive
effects of hepatocyte nuclear factor 4a on KRAS expression and
hepatocellular carcinoma malignancy [17]. Therefore, we hypothe-
sized that miR-134 might be a suppressor of HuECSCs. Following
bioinformatics analysis and ﬁreﬂy luciferase reporter assay, we
identiﬁed POGLUT1 as a target gene of miR-134. Currently, some
studies preliminary elucidated relation between POGLUT1 and the
Notch pathway [19,20]. Wang and Ma et al. showed that
knockdown of POGLUT1 expression inﬂuenced ligand induced
Notch activation, and weakened proliferation of leukemia U937
cell through CDKI-RB signalling pathway [19]. But also, they found
that POGLUT1 did not affect the binding of cell surface Notch1 to
either Delta1 or Jagged1, which might be related with different role
of O-fucosylation and O-glucosylation in modulating Notch sig-
nalling (Because O-fucosylation inducing ligand binding to Notch1
receptors, but O-glucosylation inducing ligand cleaving Notch1
receptors) [19]. In addition, Chu and Wang et al. indicated that
POGLUT1 was overexpressed in primary acute myelogenousleukaemia, T-acute lymphoblastic leukaemia samples and other
leukaemia cell lines. And, POGLUT1 promoted Notch pathway acti-
vation through CDKI-RB signalling [20]. Thus, two studies on
POGLUT1 suggested that its overexpression enhances Notch signal-
ling pathway activation and stimulates cancer cell proliferation
[19,20]. The Notch signalling pathway is established as being
highly conserved, from Drosophila to mammals, and it regulates a
wide range of cell fate decisions through direct cell–cell contact
[19,20]. The Notch signalling pathway is regulated by many post-
translational modiﬁcations, especially glycosylation [19,20]. Two
unusual forms of modiﬁcation of the Notch extracellular domain
are O-fucosylation and O-glucosylation [19,20]. O-fucose is added
by O-fucosyltransferase 1 (Ofut1/Pofut1 in Drosophila and mam-
mals) and elongated by Fringe, and the roles of both in Notch sig-
nalling have been studied extensively [19,20]. However, the
possible roles of miR-134, the related target gene Poglut1, and
miR-134 regulation of the Notch pathway in HuECSCs are still
not well elucidated.
The present study results demonstrate that miR-134 overex-
pression in HuECSCs downregulated the expression of POGLUT1
and Notch signalling pathway proteins NOTCH1, CBF1, and
HES1 but upregulated the expression of the cell cycle-related
gene p27. miR-134 overexpression also reduced HuECSCs prolif-
eration and migration, both in vitro and in vivo. Thus, miR-
134, which is a part of the DLK1-DIO3 miRNA cluster, has a
potential ability to attenuate proliferation and migration of
HuECSCs by targeting POGLUT1 and Notch pathway protein
expression.
Fig. 4. MiR-134 inhibits HuECSCs growth and migration in vivo. WT and Mut miR-134-transfected HuECSCs were subcutaneously inoculated into severe combined
immunodeﬁcient mice. (A) Xenograft tumours after 12 weeks. (B) WT miR-134 expression delayed tumour growth: tumours grew more slowly in the WT miR-134-
transfected group than in the Mut miR-134-transfected group. ⁄⁄P < 0.01 vs. miR-mut-transfected group, #P > 0.05 vs. miR-mut-transfected group; n = 5. (C) Tumour weights
at 12 weeks. ⁄⁄P < 0.01 vs. miR-mut-transfected group, #P > 0.05 vs. miR-mut-transfected group; n = 5. (D) HE-stained tumour tissues in the WT and Mut miR-134-transfected
groups revealing cellular heterogeneity; magniﬁcation, 200. Representative sections were categorized as moderately or poorly differentiated EC. (E) Immunohistochemical
staining showing positive or strongly positive Ki-67 and ER staining in tumours formed from Mut miR-134-transfected HuECSCs. In comparison, tumours formed from WT
miR-134-transfected cells show weak staining; magniﬁcation, 200.
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